- Home
- CRF vs ANAB Comparison
CRF vs ANAB Comparison
Compare CRF & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRF | ANAB |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 1997 | 2015 |
Fundamental Metrics
Financial Performance| Metric | CRF | ANAB |
|---|---|---|
| Price | $7.41 | $55.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $62.20 |
| AVG Volume (30 Days) | ★ 1.7M | 408.9K |
| Earning Date | 01-01-0001 | 04-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $91,280,000.00 |
| Revenue This Year | N/A | $135.51 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 432.03 |
| 52 Week Low | $5.81 | $14.01 |
| 52 Week High | $8.25 | $57.74 |
Technical Indicators
Market Signals| Indicator | CRF | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 43.44 | 59.87 |
| Support Level | $6.76 | $43.67 |
| Resistance Level | $8.01 | $57.65 |
| Average True Range (ATR) | 0.21 | 3.44 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 63.00 | 77.64 |
Price Performance
Historical ComparisonAbout CRF Cornerstone Total Return Fund Inc. (The)
Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology; Health Care; Financials; Communication Services; Consumer Discretionary; Industrials; Exchange-Traded Funds; Utilities; Energy; Real Estate and others.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).